| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 28 Jan 2025 | 13 Jan 2025 |
| Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31st December 2024 Outcome of Board Meeting of Piramal Pharma Limited (Company) held on 28th January 2025. (As Per Bse Announcement Dated on 28.01.2025) | ||
| Board Meeting | 23 Oct 2024 | 14 Oct 2024 |
| Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September 2024 Please refer attachment (As per BSE Announcement Dated on 23/10/2024) | ||
| Board Meeting | 30 Sep 2024 | 30 Sep 2024 |
| Intimation of Press Release announcing capacity expansion plan approved at the meeting of the Administrative Committee of the Board, today, on 30th Sept, 2024 | ||
| Board Meeting | 26 Jul 2024 | 15 Jul 2024 |
| Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2024 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2024 As per attachment. (As Per BSE Announcement dated on 26.07.2024) | ||
| Board Meeting | 10 May 2024 | 30 Apr 2024 |
| Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the Audited Financial Results (Standalone and Consolidated) for the financial year ended 31st March 2024 and to consider recommending payment of dividend to the shareholders. Please refer attachment. (As per BSE Announcement Dated on 10/05/2024) | ||
Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in these regions.
This month, the US FDA inspected the facility and after inspection issued a Form 483 of six observations as the company has to improve compliance in this regard.
In response to growing demand of IA, capacity expansions are under way at both Dahej and Digwal facilities, with month-on-month production growth.
As part of long-term strategy PCC has seen a number of product launches during recent times which are building block towards market presence in generic injectables.
The transaction falls in the internal transaction category because the parent is trading with a subsidiary.
Piramal Pharma Solutions (PPS) is set to invest $80 million in expanding its sterile injectables facility in Lexington, Kentucky, USA, projected for completion by FY27.
Piramal Pharma Limited's Chairperson, Nandini Piramal, attributed the company's development to its solid operational performance.
On September 11, 2024, and October 26, 2023, the stock reached a 52-week high of ₹244.10 and a low of ₹87.55.
Here are some of the stocks that may see significant price movement today: HCL Technologies, Lupin, Piramal Pharma, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
